in a Pandemic

2020 Virtual Nanomedicine Symposium


Thank you to all the participants, look for our next Symposium coming next fall. 

With over 800 attendees, 300 questions asked and answered, and 13 speakers, you made PNI's first Virtual Nanomedicine Symposium a great success!


We will be sending out links to the sessions in the first week of August for those who attended the symposium and would like links to the recorded sessions. 


If you could not attend the and would like to learn more about nanomedicine and view the recordings from the symposium, please fill out the form below, and we will be in touch with you.


The purpose of the RNA Symposium was to explore the necessary foundation to rapidly commercialize a COVID-19 vaccine and lay the groundwork to revolutionize future epidemic response. This area of research significantly expands the known boundaries of the human genome and offers scientists and clinicians new avenues to understand the causes and treatment of disease.

Speakers Logos

July 23, 2020

Program Overview





Session 1: RNA Treatments and Vaccines for Infectious Disease Response


The Current Landscape

Introductory Information on RNA

Platform Technologies and Future Pandemic Preparedness

The Target Product Profile for RNA Vaccines


Session 2: RNA and Delivery Platform Technologies (Choose one from four breakout sessions)


Breakout A: Basics of RNA and RNA vaccines—

Sourcing enzymes IVT


 Breakout B: Intro to RNA Delivery Technologies 

Breakout C: Antigen Design Strategies

Breakout D: Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines


Session 3: RNA Vaccine Demonstration:


Recreating formulations used in proof-of-concept studies in 2012 (Geall et al.) which was the first PoC demonstration of RNA-LNP vaccine, this time, using the NanoAssemblr® Platform, including the GMP System


Session 4: Manufacturing Platform Technology—Panel Discussion

Evolution of Various Approaches to Lipid Nanoparticle Production

Panel Discussion: How PNI Can Take Care of Lipids and LNPs for GMP Manufacturing 

Concluding remarks: Implications of COVID-19 for RNA Medicines for Other Indications




Featured Speakers (confirmed)


Dr. Luis Brito, Moderna, Inc.

Dr. Yvonne Perrie, University of Strathclyde   

Dr. Anton McCaffrey, TriLink

Dr. G Brett Robb, New England Biolabs

Annie Dosey, University of Washington

Dr. Lloyd Jeffs, Precision Nanosystems

Dr. Guarav Sahay, Oregon State University

Dr. Frank Slack, Harvard Medical School

Jessica Madigan, Trilink

Dr. Bijoyita Roy, New England Biolabs

Dr. Andy Geall Precision Nanosystems

Dr. Suraj Abraham, Precision Nanosystems


Stay Informed

Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.